Fed’s Powell opens door to potential rate cuts at Jackson Hole
Samuel Kintz, the President and CEO of Enliven Therapeutics, Inc. (NASDAQ:ELVN), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Kintz sold 12,500 shares of common stock on March 17 at an average price of $20.8256 per share, totaling approximately $260,320. The $1.02 billion market cap company maintains a strong financial position, with InvestingPro data showing more cash than debt on its balance sheet and an impressive current ratio of 19.99.
The sale was conducted under a Rule 10b5-1 trading plan, which Kintz adopted in November 2024. This plan allows insiders to set up a predetermined schedule for selling stocks to avoid any potential accusations of insider trading. While the stock currently trades near $20.89, analysts maintain an optimistic outlook with price targets ranging from $33 to $42. InvestingPro analysis suggests the stock is slightly overvalued at current levels, with additional insights available through the subscription service.
Following this transaction, Kintz holds 990,392 shares indirectly through The Kintz & Egan Trust, for which he serves as a trustee. The shares were sold at prices ranging from $20.09 to $21.04, reflecting a weighted average sale price.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.